Data on the third shot of the domestically-made new crown inactivated vaccine is released, which can induce a strong antibody response in people over 3 years old

On August 10, Sinopharm Sino Biotech announced the Phase 1/2 clinical trial data of the third dose of the inactivated COVID-19 vaccine for people over 3 years old in China
.

The results showed that after 3 doses of the vaccine were administered to people over 3 years old, the safety and tolerance were good, and it could induce a strong antibody response

Picture from Chinese Biology

The picture is from Chinese creatures The picture is from Chinese creatures

This is a randomized, double-blind, placebo-controlled trial.
Participants receive booster vaccines on a schedule of 0, 28, and 56 days
.

In terms of adverse reactions, the incidence of total adverse reactions after the third dose was not significantly different from that of only two doses of vaccine.

Immunogenicity research data show that in this clinical trial, the GMT of the anti-neovirus neutralizing antibody 28 days after the second dose of the 18-59 year old was 209.
3, and the GMT of the anti-neovirus neutralizing antibody 28 days after the third dose was 308.
4
.

For people over 60 years of age, the GMT of the neutralizing antibody against COVID-19 in the middle dose group was 118.

In the minor population, the anti-neovirus neutralizing antibody GMTs of subjects aged 13-17 years were 156.
7 and 199.
1 28 days after the second dose and the third dose, respectively
.

The GMT of the anti-neovirus neutralizing antibody 28 days after the second dose and the third dose of subjects 6-12 years old were 168.

In general, Sinopharm's new crown inactivated vaccine is safe and well tolerated after 3 doses in people over 3 years old.
After 3 doses, compared with 2 doses of vaccine, GMT is significantly improved
.

Three doses of vaccination can greatly improve the protective effect of the vaccine

It is reported that in June this year, Sinopharm Sinopharm launched the "New Coronavirus Inactivated Vaccine (Vero cell) booster immunization clinical trial in people over 18 years of age" in the UAE, and has now completed booster immunization among 9,039 people
.

In addition to the clinical trials of inactivated vaccine boosters, there are also sequential immunization strategies combined with different technical routes in China
.

On August 9th, Ai Diweixin announced that its new crown DNA vaccine candidate has been approved to cooperate with the Kellyford? (CoronaVac) Inactivated vaccines are conducting clinical trials to explore sequential immunization strategies
.

The test is divided into two specifically, one is to explore the effect of boosting the immunization of the new crown DNA vaccine after healthy adults over 18 years of age vaccinated with the new crown DNA vaccine, and the other is to vaccinate healthy adults and the elderly with different doses of the new crown DNA vaccine.

Leave a message here